manufacturer

Cutting the risks of injury and contamination

Austrian firm Greiner Bio-One is presenting products for the pre-analysis and diagnostics industry at this year’s Medica. Vacuette safety products have been developed to minimise this risk of injuries from contaminated puncture devices – a significant safety hazard to healthcare workers, the firm underlines.

The Vacuette Quickshield Safety Tube
Holder
The Vacuette Quickshield Safety Tube Holder

‘Special product solutions, such as the Vacuette Quickshield Safety Tube Holder with 360° rotatable safety shield, or the Vacuette Premium Blood Collection Tubes with safety screw cap, reduce the risk of injury or contamination to an absolute minimum.’ For rapid identification of nosocomial infections, Greiner Bio-One developed Genspeed, a molecular diagnostics system that combines crude lysis of bacteria with multiplex PCR followed by automated analysis of PCR products in the new Genspeed R2 analyser.

‘The Genspeed Test System stands out in terms of speed and high sensitivity,’ the manufacturer points out. ‘Analyses of individual samples can be made at any time. The three controls (for DNA amplification, hybridisation, as well as a negative control) on the Test Chip guarantee maximum reliability.’ The system is also reported to be compact and maintenance-free and easy to use. ‘Pre-filled reagents and the automated Genspeed R2 analyser reduce the number of process steps to a minimum,’ Grenier Bio-One adds about this newly available in Europe product. ‘One example is the Genspeed MRSA Test, a DNA-based, in-vitro, diagnostic tool for the qualitative detection of MRSA within 75 minutes from human nasal and pharyngeal smears. It features the detection of the two relevant resistance genes, mecA and mecC.’

 

Greiner Bio-One is at Medica 
Hall 03 / Stand G60

10.11.2014

More on the subject:

Related articles

Photo

News • tRNA reprogramming mechanism identified

New therapeutic target to curb coronavirus spread

Coronaviruses can generate new variants capable of infecting humans after circulating in animal reservoirs. Researchers develop broad-spectrum antiviral drugs to curb the spread of these pathogens.

Photo

News • At least 18 years of reduced risk

Cervical cancer: study confirms long-term protection from HPV vaccination

Vaccination against human papillomavirus (HPV) reduces the risk of cervical cancer for at least 18 years, according to a new study. There were no signs of waning protection over time.

Photo

News • Residual lung abnormality

Promising biomarker detects lingering lung damage after Covid-19

A new study into the long-term health impacts of coronavirus has found changes in the blood after Covid-19 that might pinpoint patients at risk of ongoing lung disease.

Subscribe to Newsletter